I-MAB/IMAB

$1.77

1.72%
-
1D1W1MYTD1YMAX

About I-MAB

I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.

Ticker

IMAB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Rajkumar Kannan

Employees

220

Headquarters

Rockville, United States

I-MAB Metrics

BasicAdvanced
$142M
Market cap
-
P/E ratio
-$2.43
EPS
1.09
Beta
-
Dividend rate
$142M
1.08803
$3.38
$1.16
250K
5.674
1.744
-42.63%
-43.84%
-63.34%
-53.14%
37.084
0.595
0.641
112.48%
42%
-73.83%

What the Analysts think about I-MAB

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 5 analysts.
1,368.93% upside
High $101.00
Low $5.00
$1.77
Current price
$26.00
Average price target

I-MAB Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-8,769.62% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
¥7.9M
-59.69%
Net income
-¥693M
-10.34%
Profit margin
-8,769.62%
122.45%

I-MAB Earnings Performance

Earnings per share (EPS)

Company profitability
-
QuarterlyAnnual
Q3 22
Q4 22
Q1 23
Q2 23
Q3 23
Actual
-
-
-
-
-
Expected
-$0.49
-$0.80
-$0.27
-$0.79
-$0.26
Surprise
-
-
-
-
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for I-MAB stock?

I-MAB (IMAB) has a market cap of $142M as of May 29, 2024.

What is the P/E ratio for I-MAB stock?

The price to earnings (P/E) ratio for I-MAB (IMAB) stock is 0 as of May 29, 2024.

Does I-MAB stock pay dividends?

No, I-MAB (IMAB) stock does not pay dividends to its shareholders as of May 29, 2024.

When is the next I-MAB dividend payment date?

I-MAB (IMAB) stock does not pay dividends to its shareholders.

What is the beta indicator for I-MAB?

I-MAB (IMAB) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the I-MAB stock price target?

The target price for I-MAB (IMAB) stock is $26, which is 1368.93% above the current price of $1.77. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell I-MAB stock

Buy or sell I-MAB stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing